Plasma p-tau217 Accurately Detects Alzheimer’s Co-pathology in Cerebral Amyloid Angiopathy
Personalized briefing
Discovery of the day · Neurology
Plasma p‐tau217 detects Alzheimer’s disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Plasma p-tau217 demonstrates high diagnostic accuracy (AUC = 0.920) for identifying Alzheimer’s disease co-pathology in patients with cerebral amyloid angiopathy, as validated against CSF-defined AD status in the ANGMAR cohort of 231 participants. The study found that predefined plasma p-tau217 cut-offs (≥0.27 and ≥0.34 pg/mL) reliably distinguished CAA patients with AD co-pathology from those without, while showing no association with MRI markers of CAA burden, confirming its specificity for AD-related rather than vascular pathology. This finding offers a minimally invasive blood-based diagnostic tool that could substantially improve clinical stratification and therapeutic decision-making for the mixed vascular-neurodegenerative phenotypes you encounter in translational neuroscience research.
Novelty
91%
Rigor
94%
Significance
90%
Validity
88%
Clarity
87%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
